
FDA Approves Vutrisiran for ATTR-CM, Expanding Indication in Amyloidosis
The FDA has approved vutrisiran (Amvuttra; Alnylam Pharmaceuticals) for the treatment of cardiomyopathy associated with wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults.1 This expanded indication makes vutrisiran both the …